Kintz Samuel's most recent trade in Enliven Therapeutics Inc was a trade of 10,393 Common Stock done at an average price of $20.0 . Disclosure was reported to the exchange on Aug. 18, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 20.02 per share. | 18 Aug 2025 | 10,393 | 929,999 | - | 20.0 | 208,106 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 18 Aug 2025 | 1,517 | 927,892 | - | 20.0 | 30,343 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 18 Aug 2025 | 590 | 929,409 | - | 20 | 11,800 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 22.69 per share. | 17 Jul 2025 | 4,687 | 944,055 | - | 22.7 | 106,360 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 21.58 per share. | 17 Jul 2025 | 4,150 | 948,742 | - | 21.6 | 89,552 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 23.37 per share. | 17 Jul 2025 | 3,663 | 940,392 | - | 23.4 | 85,607 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 22.08 per share. | 17 Jun 2025 | 10,502 | 954,890 | - | 22.1 | 231,839 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 22.75 per share. | 17 Jun 2025 | 1,998 | 952,892 | - | 22.7 | 45,453 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 20.05 per share. | 03 Jun 2025 | 7,500 | 965,392 | - | 20.0 | 150,352 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 16.49 per share. | 19 May 2025 | 5,000 | 972,892 | - | 16.5 | 82,453 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 20.08 per share. | 01 May 2025 | 5,330 | 980,062 | - | 20.1 | 107,007 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 20.00 per share. | 01 May 2025 | 2,170 | 977,892 | - | 20.0 | 43,409 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 16.42 per share. | 17 Apr 2025 | 5,000 | 985,392 | - | 16.4 | 82,096 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 20.83 per share. | 17 Mar 2025 | 12,500 | 990,392 | - | 20.8 | 260,320 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Feb 2025 | 490,000 | 490,000 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 30.00 per share. | 18 Oct 2024 | 924 | 1,002,892 | - | 30.0 | 27,723 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 28.07 per share. | 08 Oct 2024 | 13,880 | 1,006,646 | - | 28.1 | 389,675 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 27.95 per share. | 08 Oct 2024 | 13,167 | 1,020,626 | - | 28.0 | 368,078 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 28.53 per share. | 08 Oct 2024 | 2,830 | 1,003,816 | - | 28.5 | 80,730 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 28.51 per share. | 08 Oct 2024 | 100 | 1,020,526 | - | 28.5 | 2,851 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 27.51 per share. | 04 Oct 2024 | 12,206 | 1,036,523 | - | 27.5 | 335,792 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 27.50 per share. | 04 Oct 2024 | 2,730 | 1,033,793 | - | 27.5 | 75,075 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 27.54 per share. | 01 Oct 2024 | 526 | 1,048,729 | - | 27.5 | 14,485 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 22.89 per share. | 26 Aug 2024 | 12,000 | 1,049,255 | - | 22.9 | 274,718 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 27.56 per share. | 31 Jul 2024 | 2,270 | 1,061,255 | - | 27.6 | 62,555 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 25.10 per share. | 25 Jul 2024 | 8,164 | 1,063,568 | - | 25.1 | 204,920 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 24.53 per share. | 25 Jul 2024 | 3,793 | 1,071,732 | - | 24.5 | 93,042 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 25.84 per share. | 25 Jul 2024 | 43 | 1,063,525 | - | 25.8 | 1,111 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 21.63 per share. | 25 Jun 2024 | 11,422 | 1,076,103 | - | 21.6 | 247,014 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 22.30 per share. | 25 Jun 2024 | 578 | 1,075,525 | - | 22.3 | 12,887 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 28 May 2024 | 12,000 | 12,000 | - | 1.1 | 13,440 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 May 2024 | 12,000 | 188,841 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 22.86 per share. | 28 May 2024 | 6,681 | 5,319 | - | 22.9 | 152,756 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 23.57 per share. | 28 May 2024 | 5,219 | 100 | - | 23.6 | 123,020 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 24.34 per share. | 28 May 2024 | 100 | 0 | - | 24.3 | 2,434 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 25 Apr 2024 | 12,000 | 12,000 | - | 1.1 | 13,440 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 16.89 per share. | 25 Apr 2024 | 12,000 | 0 | - | 16.9 | 202,700 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Apr 2024 | 12,000 | 200,841 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Apr 2024 | 47,709 | 212,841 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 25.04 per share. | 11 Apr 2024 | 47,709 | 0 | - | 25.0 | 1,194,700 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 11 Apr 2024 | 47,709 | 47,709 | - | 1.1 | 53,434 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 25 Mar 2024 | 12,000 | 12,000 | - | 1.1 | 13,440 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Mar 2024 | 12,000 | 260,550 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 17.17 per share. | 25 Mar 2024 | 7,329 | 4,671 | - | 17.2 | 125,820 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 18.16 per share. | 25 Mar 2024 | 4,671 | 0 | - | 18.2 | 84,841 | Common Stock |
| Enliven Therapeutics Inc | Kintz Samuel | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 26 Feb 2024 | 12,000 | 12,000 | - | 1.1 | 13,440 | Common Stock |
| Enliven Therapeutics Inc | Kintz Samuel | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Feb 2024 | 12,000 | 272,550 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 16.69 per share. | 26 Feb 2024 | 7,624 | 4,376 | - | 16.7 | 127,219 | Common Stock |
| Enliven Therapeutics Inc | Kintz Samuel | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 17.24 per share. | 26 Feb 2024 | 4,376 | 0 | - | 17.2 | 75,435 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 410,000 | 410,000 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Kintz Samuel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 25 Jan 2024 | 12,000 | 12,000 | - | 1.1 | 13,440 | Common Stock |
| Enliven Therapeutics Inc | Kintz Samuel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Jan 2024 | 12,000 | 284,550 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Kintz Samuel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 15.89 per share. | 25 Jan 2024 | 9,458 | 0 | - | 15.9 | 150,257 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 14.94 per share. | 25 Jan 2024 | 2,542 | 9,458 | - | 14.9 | 37,972 | Common Stock |
| Enliven Therapeutics Inc | Kintz Samuel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Dec 2023 | 12,000 | 296,550 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Kintz Samuel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 26 Dec 2023 | 12,000 | 12,000 | - | 1.1 | 13,440 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 14.64 per share. | 26 Dec 2023 | 12,000 | 0 | - | 14.6 | 175,709 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 13.05 per share. | 21 Dec 2023 | 8,175 | 0 | - | 13.0 | 106,655 | Common Stock |
| Enliven Therapeutics Inc | Kintz Samuel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2023 | 8,175 | 308,550 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Kintz Samuel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 21 Dec 2023 | 8,175 | 8,175 | - | 1.1 | 9,156 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 13.00 per share. | 21 Dec 2023 | 20 | 0 | - | 13 | 260 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Dec 2023 | 20 | 316,725 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Kintz Samuel | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.10 per share. | 21 Dec 2023 | 20 | 20 | - | 1.1 | 22 | Common Stock |
| Enliven Therapeutics Inc | Kintz Samuel | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 13.01 per share. | 20 Dec 2023 | 7,779 | 0 | - | 13.0 | 101,238 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Dec 2023 | 7,779 | 316,745 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Samuel Kintz | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 20 Dec 2023 | 7,779 | 7,779 | - | 1.1 | 8,712 | Common Stock |
| Enliven Therapeutics Inc | Samuel Kintz | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 04 Apr 2023 | 452,000 | 452,000 | - | - | Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Samuel Kintz | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 1,087,525 | 1,087,525 | - | - | Common Stock | |
| Enliven Therapeutics Inc | Samuel Kintz | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 404,363 | 404,363 | - | - | Employee Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Samuel Kintz | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 344,550 | 344,550 | - | - | Employee Stock Option (right to buy) | |
| Enliven Therapeutics Inc | Samuel Kintz | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 88,531 | 88,531 | - | - | Common Stock | |
| Enliven Therapeutics Inc | Samuel Kintz | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 88,531 | 88,531 | - | - | Common Stock |